Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization
Autor: | S F, Kemp, R F, Lockey, F E R, Simons, F Estelle R, Simons |
---|---|
Rok vydání: | 2008 |
Předmět: |
lcsh:Immunologic diseases. Allergy
Pulmonary and Respiratory Medicine Drug Pediatrics Allergy medicine.medical_specialty Epinephrine media_common.quotation_subject Immunology Alternative medicine Review Article Appropriate use Severity of Illness Index prevention Risk Factors Acute anaphylaxis Humans Immunology and Allergy Medicine Sympathomimetics Intensive care medicine Anaphylaxis Contraindication media_common business.industry medicine.disease Treatment Outcome Anesthesia lcsh:RC581-607 business management medicine.drug Medical literature |
Zdroj: | World Allergy Organization Journal, Vol 1, Iss, Pp S18-S26 (2008) The World Allergy Organization Journal |
ISSN: | 1398-9995 0105-4538 |
DOI: | 10.1111/j.1398-9995.2008.01733.x |
Popis: | Anaphylaxis is an acute and potentially lethal multisystem allergic reaction. Most consensus guidelines for the past 30 years have held that epinephrine is the drug of choice and the first drug that should be administered in acute anaphylaxis. Some state that properly administered epinephrine has no absolute contraindication in this clinical setting. A committee of anaphylaxis experts assembled by the World Allergy Organization has examined the evidence from the medical literature concerning the appropriate use of epinephrine for anaphylaxis. The committee strongly believes that epinephrine is currently underused and often dosed suboptimally to treat anaphylaxis, is underprescribed for potential future self-administration, that most of the reasons proposed to withhold its clinical use are flawed, and that the therapeutic benefits of epinephrine exceed the risk when given in appropriate intramuscular doses. Keywords: anaphylaxis, epinephrine, management, prevention |
Databáze: | OpenAIRE |
Externí odkaz: |